Tumor Biology

, Volume 37, Issue 4, pp 5185–5192 | Cite as

Critical role of miR-155/FoxO1/ROS axis in the regulation of non-small cell lung carcinomas

  • Likun Hou
  • Jian Chen
  • Yuhui Zheng
  • Chunyan Wu
Original Article


Lung cancer is the leading cause of cancer-related deaths in the world, and non-small cell lung carcinomas (NSCLC) account for 85 % of lung cancer cases. Despite enormous achievement in the treatment of NSCLC, the molecular mechanisms underlying the pathogenesis are largely unknown. The current study was designed to evaluate the role of miR-155 in NSCLC cell proliferation and to explore the possible molecular mechanisms. We found that miR-155 expression was increased in NSCLC tissues and cell lines. The increase of miR-155 significantly increased A549 cell proliferation, decreased S phase cell population and increased G2/M phase cell population. Decrease of miR-155 expression markedly inhibited cell proliferation, increased S phase cell population, and decreased G2/M phase cell population. Increase of miR-155 significantly decreased forkhead box protein O1 (FoxO1) 3’UTR luciferase activity and expression and decrease of miR-155 notably increased FoxO1 expression. Overexpression of FoxO1 significantly inhibited miR-155-exerted increase of cell proliferation and G2/M cell population. Downregulation of FoxO1 by siRNAs significantly promoted cell proliferation, decreased S phase cell numbers, and increased G2/M cell population. Downregulation of FoxO1 markedly increased ROS level, as reflected by increased DHE staining. Moreover, when N-acetylcysteine was present, increase of cell proliferation induced by downregulation of FoxO1, and upregulation of miR-155 was significantly inhibited. In conclusion, we found that miR-155 promoted NSCLC cell proliferation through inhibition of FoxO1 and the subsequent increase of ROS generation. Our findings highlight miR-155/FoxO1/ROS axis as a novel therapeutic target for the inhibition of NSCLC growth.


miR-155 Forkhead box protein O1 Reactive oxygen species Non-small cell lung carcinomas Cell proliferation 



forkhead box protein O1




non-small cell lung carcinomas


reactive oxygen species


Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

13277_2015_4335_MOESM1_ESM.docx (72 kb)
Supplemental Fig. 1 (DOCX 71 kb)


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, et al. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014;5:1392–433.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Stinchcombe TE, Fried D, Morris DE, Socinski MA. Combined modality therapy for stage III non-small cell lung cancer. Oncologist. 2006;11:809–23.CrossRefPubMedGoogle Scholar
  5. 5.
    Scagliotti GV, Novello S. Adjuvant therapy in completely resected non-small-cell lung cancer. Curr Oncol Rep. 2003;5:318–25.CrossRefPubMedGoogle Scholar
  6. 6.
    Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest. 2013;123:5231–46.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Socinski MA. Seeking new options for the treatment of small-cell lung cancer. Lung Cancer. 2005;50 Suppl 1:S25–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Wen D, Danquah M, Chaudhary AK, Mahato RI. Small molecules targeting microRNA for cancer therapy: Promises and obstacles. J Control Release.2015.Google Scholar
  9. 9.
    Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA. MicroRNA processing and human cancer. J Clin Med. 2015;4:1651–67.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Li MH, Fu SB, Xiao HS. Genome-wide analysis of microRNA and mRNA expression signatures in cancer. ACTA Pharmacol SIN. 2015Google Scholar
  11. 11.
    Orellana EA, Kasinski AL. MicroRNAs in cancer: a historical perspective on the path from discovery to therapy. Cancer Basel. 2015;7:1388–405.CrossRefGoogle Scholar
  12. 12.
    Kishikawa T, Otsuka M, Ohno M, Yoshikawa T, Takata A, Koike K. Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J Gastroenterol. 2015;21:8527–40.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hollis M, Nair K, Vyas A, Chaturvedi LS, Gambhir S, Vyas D. MicroRNAs potential utility in colon cancer: early detection, prognosis, and chemosensitivity. World J Gastroenterol. 2015;21:8284–92.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bertoli G, Cava C, Castiglioni I. MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 2015;5:1122–43.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, et al. MiR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2011;18:465–78.CrossRefPubMedGoogle Scholar
  16. 16.
    Kim JO, Gazala S, Razzak R, Guo L, Ghosh S, Roa WH, et al. Non-small cell lung cancer detection using microRNA expression profiling of bronchoalveolar lavage fluid and sputum. Anticancer Res. 2015;35:1873–80.PubMedGoogle Scholar
  17. 17.
    Wang Y, Li J, Tong L, Zhang J, Zhai A, Xu K, et al. The prognostic value of miR-21 and miR-155 in non-small-cell lung cancer: a meta-analysis. JPN J Clin Oncol. 2013;43:813–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 2013;49:604–15.CrossRefPubMedGoogle Scholar
  19. 19.
    Xu TP, Zhu CH, Zhang J, Xia R, Wu FL, Han L, et al. MicroRNA-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. Asian Pac J Cancer Prev. 2013;14:7085–90.CrossRefPubMedGoogle Scholar
  20. 20.
    Maekawa T, Maniwa Y, Doi T, Nishio W, Yoshimura M, Ohbayashi C, et al. Expression and localization of FOXO1 in non-small cell lung cancer. Oncol Rep. 2009;22:57–64.PubMedGoogle Scholar
  21. 21.
    Ma J, Wang N, Zhang Y, Wang C, Ge T, Jin H, et al. KDM6B elicits cell apoptosis by promoting nuclear translocation of FOXO1 in non-small cell lung cancer. Cell Physiol Biochem. 2015;37:201–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhang L, Quan H, Wang S, Li X, Che X. MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition. Tumour Biol. 2015;36:8121–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Zhao JG, Ren KM, Tang J. Zinc finger protein ZBTB20 promotes cell proliferation in non-small cell lung cancer through repression of FoxO1. FEBS Lett. 2014;588:4536–42.CrossRefPubMedGoogle Scholar
  24. 24.
    Arruda LC, Lorenzi JC, Sousa AP, Zanette DL, Palma PV, Panepucci RA, et al. Autologous hematopoietic SCT normalizes miR-16, −155 and −142-3p expression in multiple sclerosis patients. Bone Marrow Transplant. 2015;50:380–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Lawrie CH. MicroRNAs and lymphomagenesis: a functional review. Br J Haematol. 2013;160:571–81.CrossRefPubMedGoogle Scholar
  26. 26.
    Yu DD, Lv MM, Chen WX, Zhong SL, Zhang XH, Chen L, et al. Role of miR-155 in drug resistance of breast cancer. Tumour Biol. 2015;36:1395–401.CrossRefPubMedGoogle Scholar
  27. 27.
    Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev. 2012;21:1236–43.CrossRefPubMedGoogle Scholar
  28. 28.
    Jurkovicova D, Magyerkova M, Kulcsar L, Krivjanska M, Krivjansky V, Gibadulinova A, et al. MiR-155 as a diagnostic and prognostic marker in hematological and solid malignancies. Neoplasma. 2014;61:241–51.CrossRefPubMedGoogle Scholar
  29. 29.
    Xu ZH, Shun WW, Hang JB, Gao BL, Hu JA. Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells. Tumour Biol. 2015;36:5485–95.CrossRefPubMedGoogle Scholar
  30. 30.
    Zhang L, Quan H, Wang S, Li X, Che X. MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition. Tumour Biol. 2015Google Scholar
  31. 31.
    Wang K, Zhang T, Dong Q, Nice EC, Huang C, Wei Y. Redox homeostasis: the linchpin in stem cell self-renewal and differentiation. Cell Death Dis. 2013;4:e537.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Bartell SM, Kim HN, Ambrogini E, Han L, Iyer S, Serra US, et al. FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun. 2014;5:3773.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Zhang S, Zhao Y, Xu M, Yu L, Zhao Y, Chen J, et al. FoxO3a modulates hypoxia stress induced oxidative stress and apoptosis in cardiac microvascular endothelial cells. PLoS ONE. 2013;8:e80342.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Kim DH, Kim JM, Lee EK, Choi YJ, Kim CH, Choi JS, et al. Modulation of FoxO1 phosphorylation/acetylation by baicalin during aging. J Nutr Biochem. 2012;23:1277–84.CrossRefPubMedGoogle Scholar
  35. 35.
    Kim W, Youn H, Kang C, Youn B. Inflammation-induced radioresistance is mediated by ROS-dependent inactivation of protein phosphatase 1 in non-small cell lung cancer cells. Apoptosis. 2015;20:1242–52.CrossRefPubMedGoogle Scholar
  36. 36.
    Gu Q, He Y, Ji J, Yao Y, Shen W, Luo J, et al. Hypoxia-inducible factor 1alpha (HIF-1alpha) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1alpha/CXCR4 pathway in non-small cell lung carcinoma cells. Oncotarget. 2015;6:10893–907.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Pathology, Shanghai Pulmonary HospitalTongji University School of MedicineShanghaiChina
  2. 2.Department of RadiologyShanghai Construction Group HospitalShanghaiChina
  3. 3.Department of PathologyFujian Medical University HospitalFuzhouChina

Personalised recommendations